82 FR 46252 - National Institute on Drug Abuse; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 191 (October 4, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 191 (October 4, 2017)
| Page Range | 46252-46253 | |
| FR Document | 2017-21265 |
[Federal Register Volume 82, Number 191 (Wednesday, October 4, 2017)] [Notices] [Pages 46252-46253] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-21265] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multi-site Clinical Trials. Date: October 19, 2017. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 301-827-5842, [email protected]. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12). Date: October 25, 2017. Time: 9:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, [email protected]. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Pathway to Independence Award (K99/R00). Date: October 25, 2017. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, [email protected]. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; (T32) Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants. Date: October 26-27, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. Contact Person: Susan O. McGuire, Ph.D. Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, [email protected]. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Exploring Novel RNA Modifications in HIV/AIDS and Substance Use Disorders (R01, R21). Date: November 1, 2017. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, [email protected]. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21). Date: November 29, 2017. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. [[Page 46253]] Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 301-827-5842, [email protected]. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: September 28, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017-21265 Filed 10-3-17; 8:45 am] BILLING CODE 4140-01-P
![46252 Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices
any institution employing her shall Rockville, MD 20852 (Telephone Conference Place: National Institutes of Health,
submit, in conjunction with each Call). Neuroscience Center, 6001 Executive
application for PHS funds, or report, Contact Person: Rudy O. Pozzatti, Ph.D., Boulevard, Rockville, MD 20852.
Scientific Review Officer, Scientific Review Contact Person: Susan O. McGuire, Ph.D.,
manuscript, or abstract involving PHS-
Branch, National Human Genome Research Scientific Review Officer, Office of
supported research in which Institute, 5635 Fishers Lane, Suite 4076, MSC Extramural Policy and Review, National
Respondent is involved, a certification 9306, Rockville, MD 20852, (301) 402–0838, Institute on Drug Abuse, National Institutes
to ORI that the data provided by pozzattr@mail.nih.gov. of Health, DHHS, 6001 Executive Blvd.,
Respondent are based on actual (Catalogue of Federal Domestic Assistance Room 4245, Rockville, MD 20852, (301) 827–
experiments or are otherwise Program Nos. 93.172, Human Genome 5817, mcguireso@mail.nih.gov.
legitimately derived and that the data, Research, National Institutes of Health, HHS) Name of Committee: National Institute on
procedures, and methodology are Drug Abuse Special Emphasis Panel; NIH
Dated: September 28, 2017. Pathway to Independence Award (K99/R00).
accurately reported in the application,
Sylvia L. Neal, Date: October 25, 2017.
report, manuscript, or abstract;
(3) to exclude herself voluntarily from Program Analyst, Office of Federal Advisory Time: 1:00 p.m. to 5:00 p.m.
Committee Policy. Agenda: To review and evaluate grant
serving in any advisory capacity to PHS
[FR Doc. 2017–21263 Filed 10–3–17; 8:45 am] applications.
including, but not limited to, service on Place: National Institutes of Health,
any PHS advisory committee, board, BILLING CODE 4140–01–P
Neuroscience Center, 6001 Executive
and/or peer review committee, or as a Boulevard, Rockville, MD 20852.
consultant for a period of three (3) years, Contact Person: Susan O. McGuire, Ph.D.,
beginning with the effective date of the DEPARTMENT OF HEALTH AND Scientific Review Officer, Office of
Agreement; and HUMAN SERVICES Extramural Policy and Review, National
(4) that as a condition of the Institute on Drug Abuse, National Institutes
National Institutes of Health of Health, DHHS, 6001 Executive Blvd.,
Agreement, Respondent will request
that PLoS One 8(8):e71868, 2013 be Room 4245, Rockville, MD 20852, (301) 827–
National Institute on Drug Abuse; 5817, mcguireso@mail.nih.gov.
corrected or retracted. Notice of Closed Meetings Name of Committee: National Institute on
FOR FURTHER INFORMATION CONTACT:
Pursuant to section 10(d) of the Drug Abuse Special Emphasis Panel; (T32)
Director, Office of Research Integrity, Ruth L. Kirschstein National Research
1101 Wootton Parkway, Suite 750, Federal Advisory Committee Act, as
Service Award (NRSA) Institutional Research
Rockville, MD 20852, (240) 453–8200. amended, notice is hereby given of the Training Grants.
following meetings. Date: October 26–27, 2017.
Kathryn M. Partin, The meetings will be closed to the Time: 8:00 a.m. to 5:00 p.m.
Director, Office of Research Integrity. public in accordance with the Agenda: To review and evaluate grant
[FR Doc. 2017–21367 Filed 10–3–17; 8:45 am] provisions set forth in sections applications.
BILLING CODE 4150–31–P 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: National Institutes of Health,
as amended. The grant applications and Neuroscience Center, 6001 Executive
the discussions could disclose Boulevard, Rockville, MD 20852.
DEPARTMENT OF HEALTH AND confidential trade secrets or commercial Contact Person: Susan O. McGuire, Ph.D.
Scientific Review Officer, Office of
HUMAN SERVICES property such as patentable material,
Extramural Policy and Review, National
and personal information concerning Institute on Drug Abuse, National Institutes
National Institutes of Health individuals associated with the grant of Health, DHHS, 6001 Executive Blvd.,
applications, the disclosure of which Room 4245, Rockville, MD 20852, (301) 827–
National Human Genome Research would constitute a clearly unwarranted 5817, mcguireso@mail.nih.gov.
Institute; Notice of Closed Meeting invasion of personal privacy. Name of Committee: National Institute on
Pursuant to section 10(d) of the Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;
Federal Advisory Committee Act, as Drug Abuse Special Emphasis Panel; Multi- Exploring Novel RNA Modifications in HIV/
amended, notice is hereby given of the site Clinical Trials. AIDS and Substance Use Disorders (R01,
following meeting. Date: October 19, 2017. R21).
Time: 1:00 p.m. to 5:00 p.m. Date: November 1, 2017.
The meeting will be closed to the
Agenda: To review and evaluate grant Time: 9:00 a.m. to 5:00 p.m.
public in accordance with the Agenda: To review and evaluate grant
applications.
provisions set forth in sections Place: National Institutes of Health, applications.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Neuroscience Center, 6001 Executive Place: National Institutes of Health,
as amended. The grant applications and Boulevard, Rockville, MD 20852, (Telephone Neuroscience Center, 6001 Executive
the discussions could disclose Conference Call). Boulevard, Rockville, MD 20852,
confidential trade secrets or commercial Contact Person: Shang-Yi Anne Tsai, Contact Person: Susan O. McGuire, Ph.D.,
property such as patentable material, Ph.D., Scientific Review Officer, Office of Scientific Review Officer, Office of
and personal information concerning Extramural Policy and Review, Division of Extramural Policy and Review, National
Extramural Research, National Institute on Institute on Drug Abuse, National Institutes
individuals associated with the grant
Drug Abuse, NIH, DHHS, 6001 Executive of Health, DHHS, 6001 Executive Blvd.,
applications, the disclosure of which Boulevard, Room 4228, MSC 9550, Bethesda, Room 4245, Rockville, MD 20852, (301) 827–
would constitute a clearly unwarranted MD 20892, 301–827–5842, shangyi.tsai@ 5817, mcguireso@mail.nih.gov.
invasion of personal privacy. nih.gov. Name of Committee: National Institute on
Name of Committee: National Human Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Cutting-
sradovich on DSK3GMQ082PROD with NOTICES
Genome Research Institute Special Emphasis Drug Abuse Special Emphasis Panel; NIDA Edge Basic Research Awards (CEBRA) (R21).
Panel, SEP U24 Research Resource. Mentored Clinical Scientists Development Date: November 29, 2017.
Date: November 30, 2017. Program Award in Drug Abuse and Time: 9:00 a.m. to 5:00 p.m.
Time: 11:00 a.m. to 2:00 p.m. Addiction (K12). Agenda: To review and evaluate grant
Agenda: To review and evaluate grant Date: October 25, 2017. applications.
applications. Time: 9:00 a.m. to 12:00 p.m. Place: Bethesda North Marriott Hotel &
Place: National Human Genome Research Agenda: To review and evaluate grant Conference Center, 5701 Marinelli Road,
Institute, 5635 Fishers Lane, Suite 3146, applications. Bethesda, MD 20852.
VerDate Sep<11>2014 20:18 Oct 03, 2017 Jkt 244001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\04OCN1.SGM 04OCN1](https://thefederalregister.org/doc/82_FR_46443/page/1.svg)
![Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices 46253
Contact Person: Shang-Yi Anne Tsai, Dated: September 28, 2017. DEPARTMENT OF HEALTH AND
Ph.D., Scientific Review Officer, Office of Natasha M. Copeland, HUMAN SERVICES
Extramural Policy and Review, Division of
Extramural Research, National Institute on Program Analyst, Office of Federal Advisory
Committee Policy. National Institutes of Health
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda, [FR Doc. 2017–21264 Filed 10–3–17; 8:45 am]
Submission for OMB Review; 30-Day
MD 20892, 301–827–5842, shangyi.tsai@ BILLING CODE 4140–01–P
nih.gov. Comment Request, The National
(Catalogue of Federal Domestic Assistance
Institute of Mental Health Data Archive
Program Nos.: 93.279, Drug Abuse and (NDA), National Institute of Mental
DEPARTMENT OF HEALTH AND Health
Addiction Research Programs, National
Institutes of Health, HHS) HUMAN SERVICES
AGENCY: National Institutes of Health.
Dated: September 28, 2017. National Institutes of Health ACTION: Notice.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory National Institute on Drug Abuse; SUMMARY: In compliance with the
Committee Policy. Notice of Closed Meeting Paperwork Reduction Act of 1995, the
[FR Doc. 2017–21265 Filed 10–3–17; 8:45 am] National Institutes of Health (NIH) has
BILLING CODE 4140–01–P Pursuant to section 10(d) of the submitted to the Office of Management
Federal Advisory Committee Act, as and Budget (OMB) a request for review
amended, notice is hereby given of the and approval of the information
DEPARTMENT OF HEALTH AND following meeting of the Board of collection listed below. This proposed
HUMAN SERVICES Scientific Counselors, NIDA. information collection was previously
published in the Federal Register on
National Institutes of Health The meeting will be closed to the
July 11, 2017, and allowed 60 days for
public as indicated below in accordance public comment. No public comments
National Institute of Allergy and with the provisions set forth in section were received. The purpose of this
Infectious Diseases; Notice of Closed 552b(c)(6), Title 5 U.S.C., as amended notice is to allow an additional 30 days
Meeting for the review, discussion, and for public comment.
Pursuant to section 10(d) of the evaluation of individual intramural
DATES: Comments regarding this
Federal Advisory Committee Act, as programs and projects conducted by the information collection are best assured
amended, notice is hereby given of a National Institute on Drug Abuse, of having their full effect if received
meeting of Microbiology, Infectious including consideration of personnel within 30-days of the date of this
Diseases and AIDS Initial Review Group qualifications and performance, and the publication.
Microbiology and Infectious Diseases competence of individual investigators,
the disclosure of which would ADDRESSES: Written comments and/or
Research Committee.
suggestions regarding the item(s)
The meeting will be closed to the constitute a clearly unwarranted
contained in this notice, especially
public in accordance with the invasion of personal privacy.
regarding the estimated public burden
provisions set forth in sections Name of Committee: Board of Scientific and associated response time, should be
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Counselors, NIDA. directed to the: Office of Management
as amended. The grant applications and Date: November 7, 2017. and Budget, Office of Regulatory Affairs,
the discussions could disclose Closed: 8:00 a.m. to 4:30 p.m. OIRA_submission@omb.eop.gov or by
confidential trade secrets or commercial Agenda: To review and evaluate personal fax to 202–395–6974, Attention: Desk
property such as patentable material, qualifications and performance, and Officer for NIH.
and personal information concerning competence of individual investigators.
individuals associated with the grant FOR FURTHER INFORMATION CONTACT: To
Place: Intramural Research Program,
applications, the disclosure of which request more information on the
National Institute on Drug Abuse, NIH, Johns
would constitute a clearly unwarranted proposed project or to obtain a copy of
Hopkins Bayview Campus, Baltimore, MD
invasion of personal privacy. the data collection plans and
21223.
instruments, contact: Melba Rojas,
Name of Committee: Microbiology, Contact Person: Joshua Kysiak, Program
NIMH Project Clearance Liaison,
Infectious Diseases and AIDS Initial Review Specialist, Biomedical Research Center,
Group; Microbiology and Infectious Diseases Intramural Research Program, National
Science Policy and Evaluation Branch,
Research Committee. Institute on Drug Abuse, NIH, DHHS, 251
Office of Science Policy, Planning and
Date: October 30–31, 2017. Bayview Boulevard, Baltimore, MD 21224,
Communications, NIMH, Neuroscience
Time: 12:00 p.m. to 5:00 p.m. 443–740–2465, kysiakjo@nida.nih.gov. Center, 6001 Executive Boulevard, MSC
Agenda: To review and evaluate grant
(Catalogue of Federal Domestic Assistance 9667, Bethesda, Maryland 20892, call
applications. 301–443–4335, or email your request,
Place: National Institutes of Health, 5601 Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National including your mailing address, to
Fishers Lane, Rockville, MD 20892 (Virtual
Institutes of Health, HHS) nimhprapubliccomments@mail.nih.gov.
Meeting).
Contact Person: Frank S. De Silva, Ph.D., Formal requests for additional plans and
Scientific Review Officer, Scientific Review Dated: September 28, 2017. instruments must be requested in
Program, Division of Extramural Activities, Natasha M. Copeland, writing.
Room #3E72A, National Institutes of Health/ SUPPLEMENTARY INFORMATION: The
sradovich on DSK3GMQ082PROD with NOTICES
Program Analyst, Office of Federal Advisory
NIAID, 5601 Fishers Lane, MSC 9834,
Committee Policy. National Institute of Mental Health
Bethesda, MD 20892934, (240) 669–5023,
fdesilva@niaid.nih.gov. [FR Doc. 2017–21266 Filed 10–3–17; 8:45 am] (NIMH), National Institutes of Health,
(Catalogue of Federal Domestic Assistance BILLING CODE 4140–01–P may not conduct or sponsor, and the
Program Nos. 93.855, Allergy, Immunology, respondent is not required to respond
and Transplantation Research; 93.856, to, an information collection that has
Microbiology and Infectious Diseases been extended, revised, or implemented
Research, National Institutes of Health, HHS) on or after October 1, 1995, unless it
VerDate Sep<11>2014 20:18 Oct 03, 2017 Jkt 244001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\04OCN1.SGM 04OCN1](https://thefederalregister.org/doc/82_FR_46443/page/2.svg)
Document Created: 2018-10-25 09:55:33
Document Modified: 2018-10-25 09:55:33
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | October 19, 2017. | |
| FR Citation | 82 FR 46252 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR